Literature DB >> 20889867

Differential West Nile fever ascertainment in the United States: a multilevel analysis.

Benjamin J Silk1, J Rex Astles, Jaime Hidalgo, Rosemary Humes, Lance A Waller, James W Buehler, Ruth L Berkelman.   

Abstract

We evaluated the completeness of West Nile fever (WNF) surveillance within the U.S. public health system. We surveyed laboratory and surveillance programs on policies, practices, and capacities for testing, confirmation, and reporting (collectively called ascertainment) from 2003 through 2005. We calculated syndrome ascertainment ratios by dividing WNF counts by neuroinvasive disease counts; separately, we performed multilevel modeling. Jurisdictions were more likely to ascertain at least one WNF cases per West Nile neuroinvasive disease case when ≤ 1 testing restrictions existed (odds ratio [OR] = 7.7, 95% confidence interval [CI] = 1.3-46.4), when conducting ≥ 4 activities to enhance reporting (OR = 9.3, 95% CI = 1.6-54.8), and when ≥ 5.0 staff per million residents were dedicated to arboviral surveillance (OR = 6.4, 95% CI = 1.0-40.3). Ascertainment of WNF was less likely among Blacks (OR = 0.56, 95% CI = 0.31-0.99) and Hispanics (OR = 0.69, 95% CI = 0.48-0.98) than among Whites. Ascertainment was more complete when testing and reporting were enhanced, but differentially incomplete for minorities.

Entities:  

Mesh:

Year:  2010        PMID: 20889867      PMCID: PMC2946744          DOI: 10.4269/ajtmh.2010.10-0161

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  29 in total

1.  Reporting race and ethnicity data--National Electronic Telecommunications System for Surveillance, 1994-1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-04-23       Impact factor: 17.586

Review 2.  Multiple imputation: a primer.

Authors:  J L Schafer
Journal:  Stat Methods Med Res       Date:  1999-03       Impact factor: 3.021

3.  Evaluations of commercial West Nile virus immunoglobulin G (IgG) and IgM enzyme immunoassays show the value of continuous validation.

Authors:  Annette K Malan; Thomas B Martins; Harry R Hill; Christine M Litwin
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

4.  Racial disparities in nationally notifiable diseases--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-01-14       Impact factor: 17.586

Review 5.  Capture-recapture methods in epidemiology: methods and limitations.

Authors:  E B Hook; R R Regal
Journal:  Epidemiol Rev       Date:  1995       Impact factor: 6.222

6.  Improving disease reporting in Los Angeles County: trial and results.

Authors:  B P Weiss; M A Strassburg; S L Fannin
Journal:  Public Health Rep       Date:  1988 Jul-Aug       Impact factor: 2.792

7.  The underreporting of disease and physicians' knowledge of reporting requirements.

Authors:  P M Konowitz; G A Petrossian; D N Rose
Journal:  Public Health Rep       Date:  1984 Jan-Feb       Impact factor: 2.792

8.  Estimated incidence and prevalence of genital Chlamydia trachomatis infections in the United States, 1996.

Authors:  S L Groseclose; A A Zaidi; S J DeLisle; W C Levine; M E St Louis
Journal:  Sex Transm Dis       Date:  1999-07       Impact factor: 2.830

9.  Persistence of West Nile Virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease.

Authors:  Hema Kapoor; Kimberly Signs; Patricia Somsel; Frances P Downes; Patricia A Clark; Jeffrey P Massey
Journal:  J Clin Virol       Date:  2004-12       Impact factor: 3.168

10.  Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases.

Authors:  John T Roehrig; Denis Nash; Beth Maldin; Anne Labowitz; Denise A Martin; Robert S Lanciotti; Grant L Campbell
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more
  3 in total

1.  Use of temperature to improve West Nile virus forecasts.

Authors:  Nicholas B DeFelice; Zachary D Schneider; Eliza Little; Christopher Barker; Kevin A Caillouet; Scott R Campbell; Dan Damian; Patrick Irwin; Herff M P Jones; John Townsend; Jeffrey Shaman
Journal:  PLoS Comput Biol       Date:  2018-03-09       Impact factor: 4.475

2.  Hospital-based enhanced surveillance for West Nile virus neuroinvasive disease.

Authors:  N P Lindsey; M Fischer; D Neitzel; E Schiffman; M L Salas; C A Glaser; T Sylvester; M Kretschmer; A Bunko; J E Staples
Journal:  Epidemiol Infect       Date:  2016-06-17       Impact factor: 4.434

3.  First autochthonous human West Nile virus infections in the Netherlands, July to August 2020.

Authors:  Danique Rm Vlaskamp; Steven Ft Thijsen; Johan Reimerink; Pieter Hilkens; Willem H Bouvy; Sabine E Bantjes; Bart Jm Vlaminckx; Hans Zaaijer; Hans Htc van den Kerkhof; Stijn Fh Raven; Chantal Bem Reusken
Journal:  Euro Surveill       Date:  2020-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.